Response to CB adoptive cell therapy and patient outcomes. Of the 31 patients treated with intensive salvage chemotherapy, followed by CB cell therapy infusion, 13 (42%) responded, whereas the remaining 18 did not respond. Overall, 12 patients (39%) had chimerism detected. Thirteen patients received HSCT at a median of 44 days after the study treatment. Arrows indicate patients alive (as of May 2020, median follow-up: 234 days); for the remaining patients, the cause of death is indicated. VOD, veno-occlusive disease.